Lux Capital

Shiru, Inc. is a food technology company based in Oakland, California, established in 2019. The company specializes in developing and producing edible proteins aimed at replacing dairy products and eggs in the food industry. By leveraging artificial intelligence and computational design, Shiru creates enhanced proteins that contribute to sustainable food production. The company's focus on using bioinformatics and precision biology allows it to discover novel natural proteins, thereby enabling clients to replace harmful ingredients with healthier alternatives.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Shiru, Inc. is a food technology company based in Oakland, California, established in 2019. The company specializes in developing and producing edible proteins aimed at replacing dairy products and eggs in the food industry. By leveraging artificial intelligence and computational design, Shiru creates enhanced proteins that contribute to sustainable food production. The company's focus on using bioinformatics and precision biology allows it to discover novel natural proteins, thereby enabling clients to replace harmful ingredients with healthier alternatives.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Shiru, Inc. is a food technology company based in Oakland, California, established in 2019. The company specializes in developing and producing edible proteins aimed at replacing dairy products and eggs in the food industry. By leveraging artificial intelligence and computational design, Shiru creates enhanced proteins that contribute to sustainable food production. The company's focus on using bioinformatics and precision biology allows it to discover novel natural proteins, thereby enabling clients to replace harmful ingredients with healthier alternatives.

Brainiac is a manufacturer specializing in brain health-focused snacks and beverages, targeting both children and adults. The company offers a range of products, including applesauce, fruit and veggie squeezies, and brain butter, all enriched with a proprietary blend of nutrients known as BrainPack. This blend includes Omega-3 DHA, Omega-3 EPA, Omega-3 ALA, choline, and lutein, which are recognized for their positive effects on brain development and function. Brainiac emphasizes the use of clean labels, organic ingredients, and BPA-free packaging, ensuring that its offerings are both nutritious and responsibly produced. Founded by two fathers with the goal of enhancing brain nutrition for their families, Brainiac is dedicated to providing healthy snack options that support brain wellness and cognitive performance. Customers can conveniently purchase these products online.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.